Need for treatment escalation · infants with bronchiolitis
Summary of findings table ‐ High‐flow nasal cannula probably leads to lower need for treatment escalation compared with standard oxygen therapy (low‐flow) (moderate certainty).
1 finding from 1 review
Duration of oxygen therapy (hours) · infants with bronchiolitis
1 finding from 1 review
Mortality Mortality at latest · preterm or low birth weight infants
Early (less than seven days following birth) higher showed no clear difference in mortality (latest time reported up to hospital discharge) compared with lower sodium intake (low certainty).
1 finding from 1 review
Neurodevelopmental disability · preterm or low birth weight infants
1 finding from 1 review
Hyponatraemia (< 130 mmol/L) · preterm or low birth weight infants
Early (less than seven days following birth) higher showed no clear difference in hyponatraemia (< 130 mmol/L) compared with lower sodium intake (low certainty).
1 finding from 1 review
Hypernatraemia (≥ 150 mmol/L) · preterm or low birth weight infants
Early (less than seven days following birth) higher showed no clear difference in hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (low certainty).
1 finding from 1 review
Postnatal growth failure · preterm or low birth weight infants
1 finding from 1 review
Necrotising enterocolitis · preterm or low birth weight infants
It is very uncertain whether early (less than seven days following birth) higher changes necrotising enterocolitis compared with lower sodium intake (very low certainty).
1 finding from 1 review
Chronic lung disease · preterm or low birth weight infants
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (selenium) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Length of hospital stay · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review